

Gestational diabetes mellitus in women born small or premature: Systematic review and meta-analysis

Yasushi Tsujimoto¹, Yuki Kataoka², Masahiro Banno³, Shunsuke Taito⁴, Masayo Kokubo⁵, Yuko Masuzawa⁶, and Yoshiko Yamamoto⁷

¹Kyoto University Graduate School of Medicine / School of Public Health

²Kyoto Min-Iren Asukai Hospital

³Seichiryō Hospital

⁴Hiroshima University Hospital

⁵Nagano Children's Hospital

⁶Tokyo Healthcare University Chiba Faculty of Nursing

⁷National Center for Child Health and Development

April 16, 2024

Abstract

Abstract Objective: Women born preterm or with low birthweight (LBW) have an increased future risk of gestational diabetes mellitus (GDM); however, a quantitative summary of evidence is lacking. Herein, we aimed to investigate whether LBW, small for gestational age (SGA) status, or preterm birth are factors associated with GDM risk; moreover, the evidence quality was assessed. **Data Sources:** We searched databases such as MEDLINE, Embase, and CINAHL and study registries including ClinicalTrials.gov and ICTRP from launch until October 29, 2020. **Methods of Study Selection:** Major electronic databases were searched from inception to October 29, 2020. Observational studies that examined the association between birth weight or gestational age and GDM were eligible. We pooled the odds ratios and 95% confidence intervals using the DerSimonian and Laird random-effects model. **Tabulation, Integration, and Results:** Eighteen studies were included ($N = 827,382$). The meta-analysis showed that being born preterm, with LBW, or with SGA status increased the risk of GDM (pooled odds ratio = 1.84; 95% confidence interval: 1.54 to 2.20; $I^2 = 78.3\%$; $\tau^2 = 0.07$). Given a GDM prevalence of 2.0%, 10%, and 20%, the absolute risk differences were 1.6%, 7.0%, and 11.5%, respectively. The certainty of evidence was low due to serious concerns of risk of bias and publication bias. **Conclusion:** Women born prematurely, with LBW, or with SGA status may be at an increased risk of GDM. However, whether this should be considered in clinical decision-making depends on the prevalence of gestational diabetes mellitus. **Protocol registration:** PROSPERO (CRD42020142004)

Introduction

Gestational diabetes mellitus (GDM) is a common pregnancy complication, with prevalence estimates being 1–36%, depending on the population studied and diagnostic criteria employed¹⁻⁵. GDM is defined as preconceptionally unconfirmed glucose intolerance identified in the second or third trimester of pregnancy⁶. Adverse perinatal outcomes associated with uncontrolled diabetes in pregnancy include spontaneous abortion, foetal anomalies, preeclampsia, stillbirth, macrosomia, neonatal hypoglycaemia, and neonatal hyperbilirubinemia, among others⁷. Women with a history of GDM are at a higher risk of type 2 diabetes than their counterparts^{8, 9}.

Low birth weight (LBW) and preterm birth are the leading causes of neonatal death and childhood-onset morbidity¹⁰⁻¹². Approximately 10–15% of infants are born small or premature worldwide^{11, 13}. Children who survive are at a higher risk of diseases, such as type 1 and 2 diabetes mellitus, hypertension, obesity,

and kidney disease, in adulthood¹⁴⁻¹⁶. The exact mechanism underlying these risks remains unclear; the Barker hypothesis proposes that pregnancy may activate biological vulnerability in utero¹⁷⁻¹⁹.

A narrative review reported in 2007 that women born with LBW are at risk of GDM²⁰, but included a small number of studies, and additional research has been published subsequently²¹⁻²⁶. There is no quantitative summary of the relevant evidence to date. We performed the first systematic review and meta-analysis of observational studies examining the association between preterm birth, with LBW, or with SGA status and the future risk of GDM.

Methods

We followed the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines (Supplementary Table S1) in the reporting of this study; the study methodology adhered to the Cochrane Handbook^{27, 28}. Evidence certainty assessment was based on the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) criteria for prognostic factors²⁹. The protocol was prospectively registered with PROSPERO (CRD42020142004).

Searches

We searched databases such as MEDLINE, Embase, and CINAHL and study registries including ClinicalTrials.gov and ICTRP from launch until 29 October 2020. Qualified authors (YT and YK) developed the search strategy (Supplementary Table S2). No language or publication status restrictions were imposed. Reference lists of shortlisted studies were searched manually for additional potentially eligible titles.

Study selection

Studies were eligible for inclusion if they were observational cohort or case-control studies. Case reports or series were excluded from the present review. We included studies that involved pregnant women regardless of study setting. The exposures of interest were the infancy parameters of presently pregnant women and were defined as follows: LBW, birth weight <2500 g¹³; small for gestational age (SGA), birth weight <10th percentile for the given gestational age, stratified by sex, using the average weight of gestational age³⁰; and preterm birth, gestational age of <37 weeks³¹. When data on both birth weight and gestational age were reported, we extracted data on birth weight in preference. The comparator group comprised women who were not born small or born at full term.

The outcome of interest was GDM, as defined by the International Association of Diabetes Pregnancy Study Groups (IADPSG), World Health Organization (WHO), American Diabetes Association or Endocrine Society, or International Classification of Diseases 11th revision (ICD-11) or earlier³²⁻³⁶. If studies used other definitions, they were included in the present review; however, we removed them to assess the robustness of the pooled estimates. For studies that reported LBW, preterm birth, or SGA as a risk factor in pregnant women without reporting the association with GDM, we contacted study authors to acquire estimates of such associations, where available. These additional estimates were included in the present analysis, provided they were measures of an association between at least one of the exposure factors and the outcome of interest.

Two investigators independently screened article titles and abstracts to shortlist relevant studies; subsequently, the same sets of authors assessed the full text for study eligibility. In cases where data were incomplete and precluded study eligibility assessment, we contacted study authors with requests for clarification. Multiple publications were assessed together; the record with the most complete data was included in the present review.

Data extraction and quality assessment

Two investigators independently extracted data from all included studies, using a pilot-tested, uniform data extraction sheet. Any discrepancies between reviewers were resolved through consensus between two reviewers or arbitration by a third reviewer, as required. For studies that compared three or more exposure groups, we contacted study authors to obtain data comparing two groups of interest. In cases where this approach was unsuitable, we extracted the relevant data, as reported, and performed subgroup comparisons between

the two groups subdivided by specific thresholds (i.e., birth weight 2500 g, <10th percentile, and gestational age 37 weeks for LBW, SGA, and preterm birth, respectively), as this approach may have resulted in conservative effect estimates. The same authors who performed data extraction also independently assessed the risk of bias in each study, using the Quality In Prognosis Studies (QUIPS) tool³⁷. We prospectively identified the following candidate confounders: age, obesity, smoking status, socioeconomic status, diabetes mellitus before the index gestation, and family history of diabetes^{38, 39}.

Data synthesis and analysis

We obtained pooled and adjusted ORs with 95% CI estimates of GDM for the exposure and control groups using the DerSimonian and Laird random-effects method. We calculated the absolute risk difference for GDM between the exposure and control groups in low- (control group: GDM risk was assumed to be 2.0%), moderate- (10%), and high- (20%) prevalence groups, using the pooled odds ratios (OR) and 95% confidence intervals (CIs). This assumption was made based on a previous report and our clinical expertise⁴⁰.

Publication bias was assessed qualitatively by visual inspection of the funnel plot and quantitatively by Egger’s test⁴¹. Where asymmetry was observed in the funnel plot, we investigated the likely source of this asymmetry using the contour-enhanced funnel plot.

We evaluated between-study heterogeneity visually, using forest plots, and quantitatively, using I^2 and τ^2 statistics. We used the Cochrane chi-square test to calculate I^2 and τ^2 statistics. We performed a pre-specified subgroup analysis based on types of exposure (preterm birth, LBW, or SGA). In pre-specified sensitivity analyses, we used crude ORs instead of adjusted ORs and excluded studies using non-standard definitions of GDM. Some studies assessed the risk of GDM among women born with a weight >4000 g (macrosomia); these studies were excluded from post-hoc sensitivity analysis, as a previous review has shown a U-shaped association between mother’s birth weight and GDM risk²⁰.

All analyses were performed using STATA 14.2 (StataCorp LP, Texas) and RevMan 5.4 (Cochrane Collaboration, UK). Two-sided p - values <0.05 were considered indicative of statistical significance.

Results

Figure 1 presents the flow of studies through the present review selection process. After screening 15,281 records, 59 records representing 44 studies were assessed for eligibility based on the full text. Finally, 18 studies including 827,382 participants were included in the qualitative synthesis; 15 studies including 825,622 participants were included in quantitative synthesis. Supplementary Table S3 lists all excluded studies with reasons for exclusion. We did not find any ongoing or unpublished studies by searching study registries. By contacting authors, we obtained unpublished data from two studies^{23, 25}.

Table 1 shows the characteristics of the included studies. Nine studies (810,197 participants) used population-based samples, 2 (6,915 participants) were multicentre studies, 6 (9,439 participants) were single-centre studies, and 1 (831 participants) did not specify the study setting. Supplementary Table S4 shows the details of the inclusion and exclusion criteria of the included studies. All studies were conducted in high-income countries, mostly between the late 1990s and early 2010s. The studies included participants of non-Hispanic White, Hispanic, African, Asian, or Indian descent. Two studies (28,722 participants) only included women about to deliver their first child. Two studies (140,714 participants) compared pregnant women born preterm and at full term, 9 (216,439 participants) compared women born with and without LBW, and 4 (468,469 participants) compared women born with and without SGA status. The remaining 3 studies (1,760 participants) only compared the mean birth weight of women with or without GDM. Figure S1 presents a summary of study quality assessment using the QUIPS tool³⁷. The overall quality of the included studies was moderate to low, mainly due to uncontrolled confounders.

Prematurity and size at birth and the risk of gestational diabetes mellitus

The median GDM rate in the control groups of the included cohort studies was 2.9% (range: 0.5% to 22%). Figure 2 presents a forest plot summarising the studies that assessed the association between preterm birth

or size at birth with GDM. Premature birth, LBW, and SGA status were associated with a higher GDM risk (pooled OR, 1.84; 95% CI: 1.54 to 2.20; $I^2 = 78.3\%$; $\tau^2 = 0.07$). Supplementary Table S5 summarises the absolute risk difference in pregnant women born with LBW, SGA status, or born preterm in the low- (2.0% risk of GDM in the control group), medium- (10%), and high- (20%) GDM prevalence groups. The absolute risk increases were 1.6% (95% CI: 1.0 to 2.1%), 7.0% (95% CI: 4.6 to 9.6%), and 11.5% (95% CI: 7.8 to 15.5%) in low-, moderate-, and high-prevalence settings, respectively. The certainty of evidence was low due to serious concerns of risk of bias and publication bias.

Figure 3 presents study estimates in a funnel plot. The plot appeared asymmetrical, and Egger's test for funnel plot asymmetry was statistically significant (p -value = 0.030). Supplementary Figure S2 shows the contour-enhanced funnel plot, which suggests the existence of some missing studies on the left-hand side of the plot; these studies would have yielded statistically non-significant findings.

Data on the birth weight of mothers with or without GDM, obtained from three studies excluded from the meta-analysis, are presented in Supplementary Table S5. These studies consistently reported that mothers with GDM were born with lower birth weights than those without GDM.

Subgroup and sensitivity analyses

There was substantial between-study heterogeneity ($I^2 = 78.3\%$). Figure 2 presents the results of subgroup analyses for the types of exposure (LBW, preterm birth, or SGA). Although all types of exposure were associated with GDM, there was significant heterogeneity due to the type of exposure (p for interaction = 0.004). The results of additional sensitivity analyses are presented in Supplementary Figure S3, Figure S4, and Figure S5.

Discussion

Main Findings

We found that women born small or premature may have future risk of GDM. However, the evidence certainty was low, and the presented findings may be overestimated, as we observed some evidence of publication bias. These findings were approximately consistent across the subgroups, including different populations, exposures, and studies of varied methodological quality; these findings were robust in sensitivity analyses.

Our finding that the mother's size at birth or premature birth may affect GDM risk was consistent with that of a previous narrative review²⁰. The strength of this association was similar to that observed in women with a family history of diabetes mellitus, an established risk factor for GDM⁴²⁻⁴⁴. However, the importance of the risk factor in clinical decision depends on the absolute risk difference. Our findings suggested that careful review of the mother's birth status may indicate her risk of GDM and guide pregnancy management in moderate to high prevalence settings. The mother's preterm birth status and size at birth are not currently considered risk factors for GDM in any of the major guidelines or risk models⁴³⁻⁴⁶. Our findings may help further refine these guidelines and models or to develop new ones.

The certainty of evidence for the association between premature birth or SGA status and GDM was low due to the high risk of publication bias, as shown by funnel-plot analysis. The contour-enhanced funnel plot suggests that studies with non-significant findings may not have been published. Although we did not identify any ongoing or unpublished studies, this did not eliminate the risk of publication bias, as observational studies are less likely to be registered than clinical trials⁴⁷. Thus, the reported estimates may be overestimates. The studies included in this review tended not to adjust for confounders, such as smoking, obesity, socioeconomic status, and family history of diabetes. Future studies should adjust for these factors.

The main result of this review was subject to substantial between-study heterogeneity, as shown by the I^2 statistic²⁷. This heterogeneity may be due to the different types of exposure (LBW, SGA, or preterm birth) considered in this study. However, as all exposure types were associated with increased GDM risk, the high I^2 statistic may be due to the large number of participants and narrow CIs of the primary studies⁴⁸. Given these findings, we did not assign a low rating to the inconsistency domain of the GRADE criteria²⁹.

The underlying mechanism of the association between preterm birth or SGA status and subsequent GDM may be gestational malnutrition due to maternal malnutrition or placental insufficiency⁴⁹. Findings from animal studies have suggested that malnutrition in utero is associated with reduced β -cell counts, pancreas weight, and pancreatic insulin content⁵⁰⁻⁵². According to the Barker foetal origin hypothesis, these foetal programming events may affect the future risk of disease¹⁷. A review of epidemiological studies has suggested that LBW and preterm birth are associated with the risk of type 2 diabetes in adulthood; a similar mechanism is possible for GDM¹⁶.

Strengths and Limitations

A key strength of this review is that it is the first to provide a comprehensive summary of evidence on the association between birth size or premature birth and future GDM risk. This study followed the methodological recommendations presented in the Cochrane Handbook, MOOSE guidelines, and GRADE criteria²⁷⁻²⁹. Moreover, this study included previously unpublished data and a large sample size.

Nevertheless, this study has some limitations. First, the included studies were old and may not represent the current clinical practice. The definition of GDM proposed by the IADPSG in 2010 has resulted in an increase in GDM prevalence^{2, 3, 53}. For example, the prevalence of GDM in the United States increased from 4.6% in 2006 to 8.2% in 2016⁵³. The median prevalence of GDM in the control groups of the included studies was 2.9%. However, empirical evidence suggests that relative effect measures are, on average, consistent across different settings; in the present study, we estimated absolute risk differences separately for low-, moderate-, and high-prevalence settings⁵⁴. Second, 5 of 15 studies divided birth size and preterm birth categories into three or more comparative groups, which could not be combined into two comparison groups of interest. This lack of data required methodological adjustments, as described previously. Lastly, this review only assessed certainty in estimates of association between prognostic factors and an outcome. Future studies are required to determine whether these factors can help risk-stratify pregnant women and improve the clinical management of GDM.

Interpretation

LBW, preterm birth, and SGA status may be prognostic factors for GDM. Clinicians should consider the prevalence of GDM in their setting when considering maternal preterm birth or size at birth in clinical decision-making. Due to the high likelihood of publication bias, the true association between the exposures and outcome of interest may be weaker than that reported herein.

Conclusions

Future studies based on up-to-date diagnostic criteria, examining the dose-response relationship between exposure severity and outcome, and comparing low- and middle-income countries, are required to improve the certainty of evidence.

Acknowledgment

We wish to thank Prof. Anne Monique Nuyt, Dr. Ariane Boivin, Dr. Prabha H. Andraweera, and Dr. Shalem Leemaqz for kindly providing additional study data that were not included in the original reports. We are also grateful to Dr. Kyosuke Kamijo and Dr. Ayako Shibata for contributing a clinical perspective. We would like to thank Editage (www.editage.com) for English language editing.

Conflict of interest

The authors have no conflicts of interest to declare.

Contribution to Authorship

YT is the guarantor of the review. YT had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: YT, YK, MB, ST, MK, YY

Acquisition, analysis, or interpretation of data: All authors

Drafting of the manuscript: YT, YK, MB, ST

Critical revision of the manuscript for important intellectual content: MK, YM, YY

Statistical analysis: YT

Administrative, technical, or material support: YT, YK, MB, ST

Study supervision: MK, YM, YY

Details of Ethics Approval

Not applicable

Funding

The English editing fee was supported by the Systematic Review Peer Support Group (not-for-profit organisation). The funders played no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

Table and figure legends

Table 1. Characteristics of the included studies

Data are presented as the mean \pm SD or number (percentage).

GDM, gestational diabetes mellitus, ICD, International Classification of Diseases; WHO, World Health Organization; SGA, small for gestational age; AGA, appropriate for gestational age; SD, standard deviation; OGTT, oral glucose tolerance test

Figure 1. PRISMA flow diagram of study eligibility

Duplicate studies are displayed as a single study.

Figure 2. Risk of gestational diabetes among women born preterm, with low birth weight, or small-for-gestational-age status

Effect size (ES, represented as adjusted odds ratios); CI, confidence interval. ES was determined using the random-effects model weighted by the inverse of the variance estimate. Squares represent ES, with marker size reflecting the statistical weight of the study, obtained using random-effects meta-analysis; horizontal lines represent 95% CIs; diamonds represent the subgroup and overall odds ratios and 95% CIs for gestational diabetes.

Figure 3. Funnel plot for the evaluation of publication bias

The solid vertical line represents the summary estimate of the association between preterm birth, low birth weight, and small for gestational age status and gestational diabetes (using random-effects meta-analysis). A significant publication bias was detected ($p = 0.030$ for Egger's test). The funnel plot shows asymmetry, which indicates publication bias.

References

1. National Collaborating Centre for Ws, Children's H. National Institute for Health and Care Excellence: Clinical Guidelines. Diabetes in Pregnancy: Management of Diabetes and Its Complications from Preconception to the Postnatal Period. London: National Institute for Health and Care Excellence (UK)

Copyright (c) 2015 National Collaborating Centre for Women's and Children's Health.; 2015.

2. Duran A, Saenz S, Torrejon MJ, Bordiu E, Del Valle L, Galindo M, et al. Introduction of IADPSG criteria for the screening and diagnosis of gestational diabetes mellitus results in improved pregnancy outcomes at a

- lower cost in a large cohort of pregnant women: the St. Carlos Gestational Diabetes Study. *Diabetes Care*. 2014;37(9):2442-50.
3. Cundy T, Ackermann E, Ryan EA. Gestational diabetes: new criteria may triple the prevalence but effect on outcomes is unclear. *Bmj*. 2014;348:g1567.
 4. Tran TS, Hirst JE, Do MA, Morris JM, Jeffery HE. Early prediction of gestational diabetes mellitus in Vietnam: clinical impact of currently recommended diagnostic criteria. *Diabetes Care*. 2013;36(3):618-24.
 5. Buchanan TA, Xiang AH, Page KA. Gestational diabetes mellitus: risks and management during and after pregnancy. *Nat Rev Endocrinol*. 2012;8(11):639-49.
 6. American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2019. *Diabetes care*. 2019;42(Supplement 1):S13-S28.
 7. American Diabetes Association. 14. Management of diabetes in pregnancy: standards of medical care in diabetes—2019. *Diabetes Care*. 2019;42(Supplement 1):S165-S72.
 8. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. *Diabetes Care*. 2002;25(10):1862-8.
 9. Bellamy L, Casas J-P, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. *The Lancet*. 2009;373(9677):1773-9.
 10. Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PFA. WHO analysis of causes of maternal death: a systematic review. *The Lancet*. 2006;367(9516):1066-74.
 11. Chawanpaiboon S, Vogel JP, Moller A-B, Lumbiganon P, Petzold M, Hogan D, et al. Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis. *The Lancet Global Health*. 2019;7(1):e37-e46.
 12. Say L, Chou D, Gemmill A, Tuncalp O, Moller A-B, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. *The Lancet Global Health*. 2014;2(6):e323-e33.
 13. United Nations Children's Fund (UNICEF) WHO. UNICEF-WHO Low birthweight estimates: Levels and trends 2000–2015. Geneva: World Health Organization; 2019.
 14. Belbasis L, Savvidou MD, Kanu C, Evangelou E, Tzoulaki I. Birth weight in relation to health and disease in later life: an umbrella review of systematic reviews and meta-analyses. *BMC Med*. 2016;14(1):147.
 15. Harder T, Roepke K, Diller N, Stechling Y, Dudenhausen JW, Plagemann A. Birth weight, early weight gain, and subsequent risk of type 1 diabetes: systematic review and meta-analysis. *Am J Epidemiol*. 2009;169(12):1428-36.
 16. Whincup PH, Kaye SJ, Owen CG, Huxley R, Cook DG, Anazawa S, et al. Birth weight and risk of type 2 diabetes: a systematic review. *Jama*. 2008;300(24):2886-97.
 17. Barker D. J. The fetal and infant origins of adult disease. *Bmj*. 1990;301(6761):1111.
 18. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice. *Hypertension*. 2018;72(1):24-43.
 19. Cheong JN, Wlodek ME, Moritz KM, Cuffe JS. Programming of maternal and offspring disease: impact of growth restriction, fetal sex and transmission across generations. *J Physiol*. 2016;594(17):4727-40.
 20. Pettitt DJ, Jovanovic L. Low birth weight as a risk factor for gestational diabetes, diabetes, and impaired glucose tolerance during pregnancy. *Diabetes Care*. 2007;30(Supplement 2):S147-S9.
 21. Rogvi R, Forman JL, Damm P, Greisen G. Women born preterm or with inappropriate weight for gestational age are at risk of subsequent gestational diabetes and pre-eclampsia. *PloS one*. 2012;7(3):e34001.

22. Chawla R, Rankin KM, Collins JW, Jr. The relation of a woman's impaired in utero growth and association of diabetes during pregnancy. *Maternal and child health journal*. 2014;18(8):2013-9.
23. Boivin A, Luo Z-C, Audibert F, Masse B, Lefebvre F, Tessier R, et al. Pregnancy complications among women born preterm. *CMAJ*. 2012;184(16):1777-84.
24. Lagerros YT, Cnattingius S, Granath F, Hanson U, Wikstrom A-K. From infancy to pregnancy: Birth weight, body mass index, and the risk of gestational diabetes. *European Journal of Epidemiology*. 2012;27(10):799-805.
25. Andraweera PH, Dekker G, Leemaqz S, McCowan L, Myers J, Kenny L, et al. Effect of Birth Weight and Early Pregnancy BMI on Risk for Pregnancy Complications. *Obesity*. 2019;27(2):237-44.
26. Ogonowski J, Miazgowski T, Engel K, Celewicz Z. Birth weight predicts the risk of gestational diabetes mellitus and pregravid obesity. *Nutrition (Burbank, Los Angeles County, Calif)*. 2014;30(1):39-43.
27. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. *Cochrane Handbook for Systematic Reviews of Interventions version 6.0*
: Cochrane; 2019 [updated July 2019. Available from: www.training.cochrane.org/handbook].
28. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *Jama*. 2000;283(15):2008-12.
29. Foroutan F, Guyatt G, Zuk V, Vandvik PO, Alba AC, Mustafa R, et al. GRADE Guidelines 28: Use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks. *J Clin Epidemiol*. 2020;121:62-70.
30. Sinha SK. *Essential neonatal medicine / Sunil Sinha, Lawrence Miall, Luke Jardine*. Jardine L, Levene MIEnm, Miall L, editors. Chichester, West Sussex ; Hoboken, NJ: Wiley-Blackwell; 2012.
31. ACOG Committee Opinion No 579: Definition of term pregnancy. *Obstet Gynecol*. 2013;122(5):1139-40.
32. World Health Organization. *ICD-11 : international statistical classification of diseases and related health problems : eleventh revision Geneva: World Health Organization; 2019 [updated 2019. Available from: <https://icd.who.int/browse11/l-m/en>*.
33. American Diabetes Association. 2. Classification and Diagnosis of Diabetes. *Diabetes Care*. 2016;39 Suppl 1:S13-22.
34. World Health Organization. *Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy*. World Health Organization; 2013.
35. Blumer I, Hadar E, Hadden DR, Jovanović L, Mestman JH, Murad MH, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab*. 2013;98(11):4227-49.
36. International Association of D, Pregnancy Study Groups Consensus P, Metzger BE, Gabbe SG, Persson B, Buchanan TA, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. *Diabetes Care*. 2010;33(3):676-82.
37. Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of prognostic factors. *Ann Intern Med*. 2013;158(4):280-6.
38. Beauregard JL, Drews-Botsch C, Sales JM, Flanders WD, Kramer MR. Does Socioeconomic Status Modify the Association Between Preterm Birth and Children's Early Cognitive Ability and Kindergarten Academic Achievement in the United States? *Am J Epidemiol*. 2018;187(8):1704-13.

39. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. *Obstetrics & Gynecology*. 2020;135(6):e237-e60.
40. Zhu Y, Zhang C. Prevalence of Gestational Diabetes and Risk of Progression to Type 2 Diabetes: a Global Perspective. *Current diabetes reports*. 2016;16(1):7-.
41. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *Bmj*. 1997;315(7109):629-34.
42. Solomon CG, Willett WC, Carey VJ, Rich-Edwards J, Hunter DJ, Colditz GA, et al. A prospective study of pregravid determinants of gestational diabetes mellitus. *Jama*. 1997;278(13):1078-83.
43. National Health Service. Gestational Diabetes [Available from: <https://www.nhs.uk/conditions/gestational-diabetes/>].
44. Centers for Disease Control and Prevention. Diabetes Risk Factors [Available from: <https://www.cdc.gov/diabetes/basics/risk-factors.html>].
45. Artzi NS, Shilo S, Hadar E, Rossman H, Barbash-Hazan S, Ben-Haroush A, et al. Prediction of gestational diabetes based on nationwide electronic health records. *Nat Med*. 2020;26(1):71-6.
46. Savvidou M, Nelson SM, Makgoba M, Messow CM, Sattar N, Nicolaides K. First-trimester prediction of gestational diabetes mellitus: examining the potential of combining maternal characteristics and laboratory measures. *Diabetes*. 2010;59(12):3017-22.
47. Boccia S, Rothman KJ, Panic N, Flacco ME, Rosso A, Pastorino R, et al. Registration practices for observational studies on ClinicalTrials.gov indicated low adherence. *J Clin Epidemiol*. 2016;70:176-82.
48. Rucker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on I(2) in assessing heterogeneity may mislead. *BMC Med Res Methodol*. 2008;8:79.
49. Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The Pathophysiology of Gestational Diabetes Mellitus. *Int J Mol Sci*. 2018;19(11).
50. Garofano A, Czernichow P, Bréant B. In utero undernutrition impairs rat beta-cell development. *Diabetologia*. 1997;40(10):1231-4.
51. McMillen IC, Robinson JS. Developmental origins of the metabolic syndrome: prediction, plasticity, and programming. *Physiol Rev*. 2005;85(2):571-633.
52. Blondeau B, Garofano A, Czernichow P, Bréant B. Age-dependent inability of the endocrine pancreas to adapt to pregnancy: a long-term consequence of perinatal malnutrition in the rat. *Endocrinology*. 1999;140(9):4208-13.
53. Zhou TAO, Sun D, Li X, Heianza Y, Nisa H, Hu G, et al. Prevalence and Trends in Gestational Diabetes Mellitus among Women in the United States, 2006–2016. *Diabetes*. 2018;67(Supplement 1):121-OR.
54. Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. *Stat Med*. 2002;21(11):1575-600.

Table 1. Characteristics of the included studies

Study	Methods	Subject characteristics	Exposure and control used in the present review	Gestational diabetes mellitus definition	Adjusted confounders in the present review	Notes
a Rogvi 2012	Design: retrospective cohort Setting: population-based Location: Denmark Sample size: 116,595	Age: 24.7 ± 2.8 Birth year: 1978 to 1981 Ethnicity: not reported Smoking: not reported Primiparous: not reported	Exposure: gestational age <37 weeks (n = 1329) Control: gestational age [?]37 weeks (n = 31,047)	GDM defined by ICD-8: 634.74 or ICD-10: O24.4	Unadjusted	Published data only
Andraweera 2019	Design: prospective cohort Setting: hospital-based (multicentre) Location: international Sample size: 5,327	Age: 28.7 ± 5.4 Birth year: not reported Ethnicity: non-Hispanic White, Asian, Polynesian, Indian, others Smoking: 566 (10.1) Primiparous: 5327 (100)	Exposure: birth weight of <2500g (n = not reported) Control: birth weight of [?]2500g (n = not reported)	GDM defined by fasting glucose [?] 5.1 mmol/L or a 2-hour level of [?] 8.5 mmol/L following an oral glucose tolerance test, according to the new WHO classification	Maternal age, smoking at 15 weeks' gestation, ethnicity, socioeconomic status, family history of diabetes, maternal gestational age at birth, infant sex, and recruitment centre.	Unpublished and published data
Bo 2003	Design: case control Setting: hospital-based (single centre) Location: Italy Sample size: 300	Age: not reported Birth year: not reported Ethnicity: not reported Smoking: 100 (33.3) Primiparous: not reported	Birth weight as a continuous variable	GDM defined by fasting glucose [?] 95 mg/dl, a 2-hour level of [?] 155 mg/dl, or a 3-hour level of [?] 140 mg/dl. Impaired glucose tolerance defined that only one glucose value was higher than above cut-off levels.	Maternal diabetes	Published data only

Study	Methods	Subject characteristics	Exposure and control used in the present review	Gestational diabetes mellitus definition	Adjusted confounders in the present review	Notes
Boivin 2012	Design: retrospective cohort Setting: population-based Location: Canada Sample size: 24,119	Age: Preterm, 23.1 ± 3.7 ; Term 23.4 ± 3.8 Birth year: 1976 to 1995 Ethnicity: not reported Smoking: not reported Primiparous: 12,130 (50.3)	Exposure: gestational age of 32 to 36 weeks (n = 6851) Control: gestational age of 37 to 42 weeks (n = 16,714)	GDM defined by ICD-9 before April 1, 2006, and the ICD-10 after April 1, 2006.	Mother's birth characteristics (SGA, large for gestational age, multiple births, and year of birth), chronic hypertension, diabetes, kidney disease, age [?] 25 years and multiple-birth pregnancy.	Unpublished and published data
Chawla 2014	Design: retrospective cohort Setting: population-based Location: US Sample size: 130,617	Age: mainly 25 to 35 Birth year: 1956 to 1976 Ethnicity: non-Hispanic White, Hispanic, and African Smoking: not reported Primiparous: 60,958 (46.7)	Exposure: SGA (n = 13,934) Control: AGA (n = 116,658)	Diabetes during pregnancy defined as pre-existing DM (including monogenic, Type 1 and Type 2) and gestational DM.	Maternal age, education, parity, plurality, marital status, and race/ethnicity	Published data only

Study	Methods	Subject characteristics	Exposure and control used in the present review	Gestational diabetes mellitus definition	Adjusted confounders in the present review	Notes
Crusell 2017	Design: case control Setting: hospital-based (single centre) Location: Denmark Sample size: 1,322	Age: mainly 26 to 28 Birth year: 1939 to 1970 Ethnicity: not reported Smoking: not reported Primiparous: not reported	Birth weight as a continuous variable	GDM based on local criteria and changed during the period: until 1987 a 3 h 50 g OGTT, and after 1987 a 3 h 75 g OGTT. GDM was diagnosed when two or more out of seven measurements exceeded the mean +3 standard deviations on a curve based on non-pregnant normal-weight women without a family history of diabetes	Unadjusted	Published data only
Egeland 2000	Design: retrospective cohort Setting: population-based Location: Norway Sample size: 138,714	Age: 14 to 31 Birth year: 1967 to 1984 Ethnicity: not reported Smoking: not reported Primiparous: not reported	Exposure: birth weight of <2500g (n = 4,652) Control: birth weight of 4000 to 4500g (n = 14,852)	Self-reported GDM in one or more pregnancies	Women's age and parity and their mother's diabetic status.	Published data only

Study	Methods	Subject characteristics	Exposure and control used in the present review	Gestational diabetes mellitus definition	Adjusted confounders in the present review	Notes
Innes 2003	Design: case control Setting: population-based Location: USA Sample size: 23,395	Age: mainly 17 to 24 Birth year: 1970 or later Ethnicity: White, non-Hispanic, Hispanic, other non-White Smoking: 4,258 (18.2) Primiparous: 23,395 (100)	Exposure: birth weight of 2000 to 2499 g (n = 1325) Control: birthweight of 3500g to 3999 g (n = 5639)	GDM defined by ICD-9 code 648.0 or abnormal glucose tolerance defined by ICD-9 code 648.8 on their hospital discharge records.	Age, race, education, employment status, pre-pregnancy body mass index, height, pregnancy weight gain, and gestational age,	Published data only
Legarros 2012	Design: retrospective cohort Setting: population-based Location: Sweden Sample size: 323,083	Age: mainly 20 to 29 Birth year: 1973 or later Ethnicity: not reported Smoking: 43,397 (13.4) Primiparous: 196,859 (60.9)	Exposure: SGA defined as more than 2 SD below the mean birth-weight-for-gestational-age (n = 12,083) Control: Birth weight 1 SD below the mean to 1 SD above the mean (n = 214,905)	GDM defined by the ICD-9 code 648W and the ICD-10 code O244, those diagnosis were mainly based on a 75 g oral glucose tolerance test with a fasting capillary whole blood glucose level C 6.1 mmol/L (plasma C 7.0 mmol/L) and/or a 2 h blood glucose C 9.0 mmol/L (plasma glucose C 10.0 mmol/L)	Body mass index height, maternal age, education, parity, smoking, and year of pregnancy	Published data only

Study	Methods	Subject characteristics	Exposure and control used in the present review	Gestational diabetes mellitus definition	Adjusted con-founders in the present review	Notes
Moses 1999	Design: case control Setting: hospital-based (single centre) Location: Australia Sample size: 138	Age: case, 26 (5.8); control, 26 (5.6) Birth year: not reported Ethnicity: not reported Smoking: not reported Primiparous: not reported	Birth weight as a continuous variable	GDM defined by fasting glucose is [?]5.5 mmol/l and/or the 2-h glucose level is [?]8.0 mmol/l, according to the criteria of the Australasian Diabetes in Pregnancy Society.	Unadjusted	Published data only
Ogonowski 2014	Design: case control Setting: hospital-based (multicentre) Location: Poland Sample size: 1,588	Age: 29.7 (0.6) Birth year: not reported Ethnicity: Caucasian Smoking: not reported Primiparous: 902 (56.8)	Exposure: birth weight of < 2500g (n = not reported) Control: birth weight of 3500 to 3999g (n = not reported)	GDM defined by either the fasting glucose was 7.0 mmol/L or the 2-h glucose concentration was 7.8 mmol/L, which was in accordance with the WHO diagnostic criteria	Age, body mass index, family history of diabetes, and prior gestational diabetes.	Published data only

Study	Methods	Subject characteristics	Exposure and control used in the present review	Gestational diabetes mellitus definition	Adjusted con-founders in the present review	Notes
Olah 1996	Design: retrospective cohort Setting: hospital-based (single centre) Location: UK Sample size: 592	Age: 27 (range 19 to 42) Birth year: not reported Ethnicity: predominantly Caucasian Smoking: not reported Primiparous: not reported	Exposure: birth weight of <2500g (n = 57) Control: birth weight of [?] 2500g (n = 452)	Impaired glucose tolerance, defined as a 2-hour plasma glucose concentration of 7.8-11.0 mmol/L, or gestational diabetes, defined as a 2-hour plasma glucose concentration of 11.1 mmol/L or more.	Unadjusted	Published data only
Pettit 1998	Design: retrospective cohort Setting: not reported Location: US Sample size: 831	Age: not reported Birth year: not reported Ethnicity: Pima Indians Smoking: not reported Primiparous: not reported	Exposure: birth weight of <2500g (n = 29) Control: birth weight of [?]2500g (n = 802)	Diabetes during pregnancy diagnosed by the WHO criteria, i.e., a glucose concentration of [?] 11.1 mmol/L 2 h after the ingestion of a 75-g glucose load	Unadjusted	Published data only

Study	Methods	Subject characteristics	Exposure and control used in the present review	Gestational diabetes mellitus definition	Adjusted con-founders in the present review	Notes
Plante 1999	Design: retrospective cohort Setting: population-based Location: US Sample size: 6,767	Age: 19 to 22 Birth year: 1974 Ethnicity: non-Hispanic White, African Smoking: not reported Primiparous: not reported	Exposure: SGA defined as a birth weight less than the tenth percentile for gestational age, race-specific for either black or white (n = 596) Control: not SGA (n = 5,954)	Diabetes on the birth certificate records. The coding was performed by the physician or other individual filling out the birth record and consisted of a checkbox in the field described as “medical complications of pregnancy.”	Unadjusted	Published data only
Plante 2004	Design: retrospective cohort Setting: population-based Location: US Sample size: 7,802	Age: 24 to 26 Birth year: 1974 Ethnicity: non-Hispanic White, African Smoking: not reported Primiparous: not reported	Exposure: SGA as defined in the Plante 1999 study (n = 537) Control: AGA as defined in the Plante 1999 study (n = 7,265)	Diabetes on the birth certificate. Specific information as to criteria for diagnosis was not available	Unadjusted	Published data only
Savona-Ventura 2003	Design: case control Setting: hospital-based (single centre) Location: Malta Sample size: 7,075	Age: not reported Birth year: 1952 to 1983 Ethnicity: not reported Smoking: not reported Primiparous: not reported	Exposure: birth weight of <2500g (n = 419) Control: birth weight of [?]2500g (n = 6,656)	GDM defined by a serum glucose concentration >8.6 mmol/l 2 hours after the OGTT.	Unadjusted	Published data only

Study	Methods	Subject characteristics	Exposure and control used in the present review	Gestational diabetes mellitus definition	Adjusted confounders in the present review	Notes
Seghieri 2002	Design: retrospective cohort Setting: hospital-based (single centre) Location: Italy Sample size: 604	Age: LBW: 31.7 (4.2) Birth year: not reported Ethnicity: not reported Smoking: not reported Primiparous: not reported	Exposure: birth weight of <2500g (n = 68) Control: birth weight of [?]2500g (n = 536)	GDM defined by the American Diabetes Association	Age, parity, family history of diabetes, and pre-pregnancy BMI,	Published data only
Williams 1999	Design: retrospective cohort Setting: population-based Location: US Sample size: 41,839 births (38,513 mothers)	Age: mainly 19 to 29 Birth year: 1949 to 1979 Ethnicity: non-Hispanic White, Hispanic, African, native American Smoking: 10,429 (24.9) Primiparous: 32,488 (77.7)	Exposure: birth weight of <2500g (n = 2,708 births) Control: birth weight of [?]2500g (n = 39,131 births)	GDM recorded on the birth certificate and/or given an ICD-9 diagnosis	Unadjusted	Published data only

Study	Methods	Subject characteristics	Exposure and control used in the present review	Gestational diabetes mellitus definition	Adjusted confounders in the present review	Notes
Data are presented as the mean \pm SD or number (percentage). GDM, gestational diabetes mellitus, ICD, International Classification of Diseases; WHO, World Health Organization; SGA, small for gestational age; AGA, appropriate for gestational age; SD, standard deviation; OGTT, oral glucose tolerance test	Data are presented as the mean \pm SD or number (percentage). GDM, gestational diabetes mellitus, ICD, International Classification of Diseases; WHO, World Health Organization; SGA, small for gestational age; AGA, appropriate for gestational age; SD, standard deviation; OGTT, oral glucose tolerance test	Data are presented as the mean \pm SD or number (percentage). GDM, gestational diabetes mellitus, ICD, International Classification of Diseases; WHO, World Health Organization; SGA, small for gestational age; AGA, appropriate for gestational age; SD, standard deviation; OGTT, oral glucose tolerance test	Data are presented as the mean \pm SD or number (percentage). GDM, gestational diabetes mellitus, ICD, International Classification of Diseases; WHO, World Health Organization; SGA, small for gestational age; AGA, appropriate for gestational age; SD, standard deviation; OGTT, oral glucose tolerance test	Data are presented as the mean \pm SD or number (percentage). GDM, gestational diabetes mellitus, ICD, International Classification of Diseases; WHO, World Health Organization; SGA, small for gestational age; AGA, appropriate for gestational age; SD, standard deviation; OGTT, oral glucose tolerance test	Data are presented as the mean \pm SD or number (percentage). GDM, gestational diabetes mellitus, ICD, International Classification of Diseases; WHO, World Health Organization; SGA, small for gestational age; AGA, appropriate for gestational age; SD, standard deviation; OGTT, oral glucose tolerance test	Data are presented as the mean \pm SD or number (percentage). GDM, gestational diabetes mellitus, ICD, International Classification of Diseases; WHO, World Health Organization; SGA, small for gestational age; AGA, appropriate for gestational age; SD, standard deviation; OGTT, oral glucose tolerance test

Hosted file

Fig1.docx available at <https://authorea.com/users/517227/articles/710555-gestational-diabetes-mellitus-in-women-born-small-or-premature-systematic-review-and-meta-analysis>

Hosted file

Fig2.docx available at <https://authorea.com/users/517227/articles/710555-gestational-diabetes-mellitus-in-women-born-small-or-premature-systematic-review-and-meta-analysis>

Hosted file

Fig3.docx available at <https://authorea.com/users/517227/articles/710555-gestational-diabetes-mellitus-in-women-born-small-or-premature-systematic-review-and-meta-analysis>